Biocept Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Biocept prevailing Real Value cannot be determined due to lack of data. The current price of Biocept is $0.0. Our model approximates the value of Biocept from analyzing the firm fundamentals such as Operating Margin of (10.38) %, return on equity of -1.87, and Shares Outstanding of 2.63 M as well as examining its technical indicators and probability of bankruptcy.
Biocept Total Value Analysis
Biocept is currently estimated to have valuation of 5.92 M with market capitalization of 1.14 M, debt of 12.11 M, and cash on hands of 27.57 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Biocept fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.92 M | 1.14 M | 12.11 M | 27.57 M |
Biocept Investor Information
The company has price-to-book (P/B) ratio of 0.37. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biocept recorded a loss per share of 48.17. The entity last dividend was issued on the 8th of September 2020. The firm had 1:30 split on the 17th of May 2023. Based on the key indicators related to Biocept's liquidity, profitability, solvency, and operating efficiency, Biocept is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Biocept Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biocept has an asset utilization ratio of 83.76 percent. This indicates that the Company is making $0.84 for each dollar of assets. An increasing asset utilization means that Biocept is more efficient with each dollar of assets it utilizes for everyday operations.Biocept Ownership Allocation
Biocept shows 9.2 percent of its outstanding shares held by insiders and 1.98 percent owned by other corporate entities.Biocept Profitability Analysis
The company reported the previous year's revenue of 25.86 M. Net Loss for the year was (32.09 M) with loss before overhead, payroll, taxes, and interest of (2.58 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Biocept's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Biocept and how it compares across the competition.
Biocept Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 17 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Biocept Stock
If you are still planning to invest in Biocept check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biocept's history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Transaction History View history of all your transactions and understand their impact on performance |